New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis

Journal of Clinical Oncology

Volumn 24, Issue 2, 2006, Pages 252-258

  Gold, David V ^a   Modrak, David E ^a   Ying, Zhiliang ^a   Cardillo, Thomas M ^a   Sharkey, Robert M ^a   Goldenberg, David M ^a  

^a Och Spine at New York Presbyterian Hospitals

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; MONOCLONAL ANTIBODY; MUC1 ANTIBODY; MUCIN 1; PAM4 ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; CA 15-3 ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME IMMUNOASSAY; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ADULT; BLOOD; IMMUNOLOGY; PANCREAS TUMOR;

ADULT; ANTIBODIES, MONOCLONAL; CA-15-3 ANTIGEN; CA-19-9 ANTIGEN; HUMANS; IMMUNOENZYME TECHNIQUES; PANCREATIC NEOPLASMS; PANCREATITIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33644815924     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.8282     Document Type: Article

References (44)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. Dalton RR, Sarr MG, vanHeerden JA, et al: Carcinoma of the body and tail of the pancreas: Is curative resection justified? Surgery 111:489-494, 1992
3. Livingston EH, Welton ML, Reber HA: Surgical treatment of pancreatic cancer: The United States experience. Int J Pancreatol 9:153-157, 1991
4. Burris III HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
5. Burris H and Storniola AM: Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil. Eur J Cancer 33:S18-S22, 1997 (suppl 1)
6. Dobelbouer RR, Howards JM, Bagne FR, et al: Treatment of cancer of the pancreas by precision high dose external photon beam and intraoperative electron beam therapy. Int J Radiat Oncol Biol Phys 16:205-209, 1989
7. Zerbi A, Fossati V, Parolini D, et al: Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer 73:2930-2935, 1994
8. Okamoto A, Tsuruta K, Isawa T, et al: Intraoperative radiation therapy for pancreatic carcinoma. Int J Pancreatol 16:157-164, 1994
9. a epitope on distinct core proteins. J Biol Chem 266:21537-21547, 1991
10. a-carrying glycoproteins produced by colon carcinoma cells using a novel monoclonalantibody. Cancer Res 53:755-761, 1993
11. x with MUC1 apomucin in a pancreatic cancer cell line. Cancer Res 55:3659-3663, 1995
12. Koprowski H, Steplewski Z, Mitchell K, et al: Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 5:957-972, 1979
13. Ritts RE, DelVillano B, Go VLW, et al: Initial clinical evaluation of an immunoradiometric assay for CA19-9 using the NCl serum bank. Int J Cancer 33:39-345, 1984
14. Steinberg W: The clinical utility of the CA19-9 tumor associated antigen. Am J Gastroenterol 85:350-355, 1990
15. Ritts RE, Pitt HA: CA19-9 in pancreatic cancer. Surg Oncolo Clin N Am 7:93-101, 1998
16. Ziske C, Schlie C, Gorschluter M, et al: Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89:1413-1417, 2003
17. Micke O, Bruns F, Kurowski R, et al: Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 57:90-97, 2003
18. Andrianifahanana M, Moniaux N, Schmied BM, et al: Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: A potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 7:4033-4040, 2001
19. Hollingsworth MA, Swanson BJ: Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer 4:45-60, 2004
20. Burdick MD, Harris A, Reid CJ, et al: Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J Biol Chem 272:24198-24202, 1997
21. Beum PV, Singh J, Burdick M, et al: Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes. J Biol Chem 274:24641-24648, 1999
22. Santos-Silva F, Fonseca A, Caffrey T, et al: Thomsen-Friedenreich antigen expression in gastric carcinomas is associated with MUC1 mucin VNTR polymorphism. Glycobiology 15:511-517, 2005
23. Epenetos AA, Britton KE, Mather S, et al: Targeting of iodine-123-labelled tumor-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet 320:999-1004, 1982
24. Berry N, Jones DB, Smallwood J, et al: The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer. Br J Cancer 51:179-186, 1985
25. Reis CA, David L, Seixas M, et al: Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer 79:402-410, 1998
26. Dalziel M, Whitehouse C, McFarlane I, et al: The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J Biol Chem 276:11007-11015, 2001
27. Burchell JM, Mungul A, Taylor-Papadimitriou J: O-linked glycosylation in the mammary gland: Changes that occur during malignancy. J Mammary Gland Biol Neoplasia 6:355-364, 2001
28. Price MR, Rye PD, Petrakou E, et al: Summary report on the ISOBM TD-4 Workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumor Biol 19:S1-S20, 1998 (suppl)
29. Gold DV, Lew K, Maliniak R, et al: Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer 57:204-210, 1994
30. 131I-labeled PAM4 antibody. Int J Cancer 71:660-667, 1997
31. 131iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res 7:3186-3192, 2001
32. 90Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 9:3929s-3937s, 2003 (suppl)
33. Mariani G, Molea N, Bacciardi D, et al: Initial targeting, biodistribution and pharmacokinetics screening of the monoclonal antibody PAM4 for immunoscintigraphy in patients with pancreatic cancer. Cancer Res 55: 5911s-5915s, 1995 (suppl)
34. Gold DV, Cardillo T, Goldenberg DM, et al: Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit Rev Oncol Hematol 39:147-154, 2001
35. Gold DV, Hollingsworth P, Kremer T, et al: Identification of a human pancreatic duct tissue-specific antigen. Cancer Res 43:235-238, 1983
36. Taylor B: Carcinoma of the head of the pancreas versus chronic pancreatitis: Diagnostic dilemma with significant consequences. World J Surg 27:1249-1257, 2003
37. National Cancer Institute Pancreatic Cancer Progress Review Group. http://prg.nci.nih.gov/pancreatic/finalreport.html 2001
38. Ho SB, Niehans GA, Lyftogt C, et al: Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 53:641-651, 1993
39. Hollingsworth MA, Strawhecker JM, Caffrey TC, et al: Expression of MUC1, MUC2, MUC3, and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. Int J Cancer 57:198-203, 1994
40. Sato N, Fukushima N, Maitra A, et al: Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol 164:903-914, 2004
41. Koopmann J, Zhang Z, White N, et al: Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10:860-868, 2004
42. Xing PX, Apostolopoulos V, Pietersz G, et al: Anti-mucin monoclonal antibodies. Front Biosci 6:1284-1295, 2001
43. Wittel UA, Goel A, Varshney GC, et al: Mucin antibodies: New tools in diagnosis and therapy of cancer. Front Biosci 6:1296-1310, 2001
44. Kim HJ, Kim MH, Myung SJ, et al: A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: Analysis using a receiver operating characteristic curve. Am J Gastroenterol 94:1942-1946, 1999